Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 67.19%
As of Friday, July 31, Karyopharm Therapeutics Inc.’s KPTI share price has dipped by 67.19%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. KPTI
$1.92
-5.09
-72.61%
July 31, 2026 4:00:00 PM
EST
Volume: 22,174,339
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Commentary & Analysis
Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 71.76%
As of Friday, July 31, Karyopharm Therapeutics Inc.’s KPTI share price has dipped by 71.76%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 8.77%
As of Wednesday, July 22, Karyopharm Therapeutics Inc.’s KPTI share price has dipped by 8.77%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 10.17%
As of Tuesday, July 21, Karyopharm Therapeutics Inc.’s KPTI share price has surged by 10.17%, which has investors questioning if this is right time to sell.Michael Rose
Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 20.56%
As of Monday, July 20, Karyopharm Therapeutics Inc.’s KPTI share price has dipped by 20.56%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | KPTI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $43.5 | $252.6 | 15% |
|
| Shares Out (Mil) | 24.7 | 52.3 | 34% |
|
| Institutional Ownership | 95.6% | 92.1% | 68% |
|
| Float (Mil) | 14.8 | 40.2 | 25% |
|
| Beta | 0.82 | 0.95 | 48% |
|
| Avg Daily Volume (000s) | 3,364 | 455 | 88% |
|
| Price Change (52-week) |
(52.6%) | 52.9% | 15% |
|
| Growth | KPTI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.2% | 13.6% | 42% |
|
| Net Income (5yr) | 0.0% | (9.9%) | 40% |
|
| EPS (5yr) | 15.2% | 16.0% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 53.9% | (15.6%) | 94% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($1.395) | ($4.805) | ($4.280) | |
| Month Ago EPS | ($1.387) | ($4.953) | ($4.890) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 2 | 0 | |
| Three Months Ago EPS | ($1.130) | ($4.777) | ($4.365) | |
| Year/Year Chg | 12.9% | (73.2%) | (95.8%) | |
| Financials | KPTI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $151 | $38 | 30% |
|
| Net Income (TTM) (Mil) | ($195) | ($43) | 7% |
|
| EPS (TTM) | ($13.614) | ($1.600) | 3% |
|
| Operating Cash Flow (TTM) (Mil) | ($59) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $52 | $5 | 71% |
|
| Long-Term Debt (Q1) (Mil) | $270 | $5 | 53% |
|
| Enterprise Value (Q1) (Mil) | $418 | $180 | 33% |
|
| Valuation | KPTI | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KPTI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 13.5% | 63.8% | 13% |
|
| Net Margin | (129.0%) | (67.3%) | 6% |
|
| ROA | (150.5%) | (49.8%) | 3% |
|
| ROE | 82.7% | (55.5%) | 95% |
|
| Liabilities to Assets | 302.1% | 30.3% | 99% |
|
| F-Score | 3 | 3 | 19% |
|
Karyopharm Therapeutics Inc. did not pass any screens on 7/31/2026.
